Salix Pharmaceuticals (NASDAQ: SLXP) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Salix Pharmaceuticals to similar companies based on the strength of its valuation, dividends, earnings, analyst recommendations, institutional ownership, profitability and risk.

Valuation and Earnings

This table compares Salix Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Salix Pharmaceuticals N/A N/A -26.55
Salix Pharmaceuticals Competitors $3.02 billion $642.98 million -26.49

Salix Pharmaceuticals’ rivals have higher revenue and earnings than Salix Pharmaceuticals. Salix Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Salix Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Salix Pharmaceuticals’ rivals have a beta of 1.24, suggesting that their average share price is 24% more volatile than the S&P 500.

Profitability

This table compares Salix Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Salix Pharmaceuticals -2,134.34% -305.24% -25.83%
Salix Pharmaceuticals Competitors -547.39% -39.23% -21.46%

Analyst Ratings

This is a summary of current ratings and recommmendations for Salix Pharmaceuticals and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Salix Pharmaceuticals 0 0 0 0 N/A
Salix Pharmaceuticals Competitors 69 338 989 29 2.69

As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 23.59%. Given Salix Pharmaceuticals’ rivals higher probable upside, analysts plainly believe Salix Pharmaceuticals has less favorable growth aspects than its rivals.

Insider & Institutional Ownership

64.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 11.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Salix Pharmaceuticals rivals beat Salix Pharmaceuticals on 8 of the 8 factors compared.

Salix Pharmaceuticals Company Profile

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

Receive News & Ratings for Salix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salix Pharmaceuticals Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.